Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

By BiotechDaily International staff writers
Posted on 16 Jun 2014
Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now.

The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals was not uniform among the constituent sectors, with the biotechnology, pharmaceutical, and healthcare equipment sectors experiencing a much sharper decline in investor interest than the healthcare technology and provider segments. Investors began to gamble on providers based with the conviction they can provide faster and safer returns than the pharmaceutical and biotechnology space, which is ridden with regulatory challenges and patent expiries.

A new market analysis from Frost & Sullivan’s (Mountain, View, CA, USA), an international growth consultancy firm, revealed the total number of PEVC transactions in the pharmaceutical and biotechnology industry decreased from 1063 in 2010 to 480 in 2013. Although the returns from the pharmaceutical and biotechnology industry have been declining, they are better compared to the performance of other industries.

“PE deals in the pharmaceutical sector have been relatively stable over the post-recession period whereas activity in the biotechnology segment began to decrease after reaching its peak in 2010, due to the uncertainty caused by healthcare reform in the US, long incubation periods, and delayed approvals,” said Frost & Sullivan financial analyst Dr. E. Saneesh. “VC deals across both these sectors also started to plummet from 2011 due to risks associated with regulatory uncertainty, long gestation periods, and increased cost of production.”

However, the strong rebirth of initial public offerings (IPOs) in 2013 indicates a positive outlook for investment in the pharmaceutical and biotechnology industry. The number of IPOs in the global biotechnology sector surged by 100% between 2012 and 2013, primarily on account of the 26 IPOs that took place in the United States. IPOs in the pharmaceutical industry also climbed with 11 deals in 2013, after the volume of IPOs declined to nearly one-sixth of the sector’s value between 2011 and 2012.

As a result of the surge in IPOs, exit opportunities are expected to increase for investors. The trend will be further fuelled by the anticipated growth of corporate investor-backed IPOs. “PEVC investors in the global pharmaceutical and biotechnology industry have demonstrated maximum interest in oncology drugs, followed by anti-infective drugs and pharmaceutical contract laboratories,” stated Dr. Saneesh. “They have also concluded the maximum pharmaceutical- and biotechnology-related PEVC deals in the US and are expected to continue to do so in the forthcoming years. Industry players most aligned with these trends will be well positioned to obtain financial support from PEVC investors.”

Related Links:

Frost & Sullivan



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.